{"id":"fec","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"60-90","effect":"Nausea and vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"20-40","effect":"Mucositis"},{"rate":"1-5","effect":"Cardiotoxicity"},{"rate":"50-70","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"dc397d9c-9c12-41e5-ab7f-196fcad5bf97","title":"MEDI FECT ANTISEPTIC HAND WASH (ETHYL ALCOHOL) LIQUID [MEDICAL CHEMICAL CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FEC combines fluorouracil (a thymidylate synthase inhibitor), epirubicin (a topoisomerase II inhibitor and intercalating agent), and cyclophosphamide (an alkylating agent). Together, these agents work synergistically to disrupt DNA synthesis and repair, leading to cancer cell death. The combination is designed to provide broad cytotoxic activity against rapidly dividing cells.","oneSentence":"FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:10.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and neoadjuvant treatment)"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT00911911","phase":"NA","title":"Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-02-22","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT04690738","phase":"","title":"Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation","status":"SUSPENDED","sponsor":"Rush University Medical Center","startDate":"2020-08-17","conditions":"Exocrine Pancreatic Insufficiency, Weight Gain","enrollment":50},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT05406115","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity","status":"COMPLETED","sponsor":"Amgen","startDate":"2022-07-26","conditions":"Obesity","enrollment":65},{"nctId":"NCT04798027","phase":"PHASE1, PHASE2","title":"Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-12","conditions":"COVID-19","enrollment":182},{"nctId":"NCT05710718","phase":"NA","title":"PureWick™ France and U.S. At-Home Pilot Study","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2023-10-31","conditions":"Nocturnal Enuresis","enrollment":17},{"nctId":"NCT03058289","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","status":"COMPLETED","sponsor":"Intensity Therapeutics, Inc.","startDate":"2017-02-09","conditions":"Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma","enrollment":111},{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":"Breast Cancer","enrollment":2017},{"nctId":"NCT02339532","phase":"PHASE2","title":"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":"Breast Cancer","enrollment":86},{"nctId":"NCT04699201","phase":"NA","title":"Trocar Site Incisional Hernia Prevention","status":"RECRUITING","sponsor":"Hospital Universitari Joan XXIII de Tarragona.","startDate":"2021-03-02","conditions":"Incisional Hernia","enrollment":94},{"nctId":"NCT01340430","phase":"PHASE2","title":"Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Lucia Del Mastro,MD","startDate":"2011-03","conditions":"HER-2 Positive Breast Cancer","enrollment":43},{"nctId":"NCT00433420","phase":"PHASE3","title":"Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2003-04","conditions":"Breast Cancer","enrollment":2000},{"nctId":"NCT06361615","phase":"NA","title":"Effect of a Dual-task Intervention Program on Physical and Cognitive Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Americas","startDate":"2023-11-08","conditions":"Functional Movement Disorder, Fragility","enrollment":24},{"nctId":"NCT01996267","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2013-12","conditions":"Breast Cancer, HER2 Positive","enrollment":437},{"nctId":"NCT01822314","phase":"PHASE3","title":"Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2013-04","conditions":"Breast Cancer","enrollment":632},{"nctId":"NCT02620280","phase":"PHASE3","title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2016-04","conditions":"Invasive Ductal Breast Carcinoma","enrollment":278},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02840890","phase":"NA","title":"Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2015-11-05","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT02659527","phase":"PHASE3","title":"PET/MRI in Patients With Suspected Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2016-01","conditions":"Prostate Cancer","enrollment":220},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT01036087","phase":"PHASE2","title":"Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-11","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT00129922","phase":"PHASE3","title":"Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-11","conditions":"Breast Cancer","enrollment":1289},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT00433589","phase":"PHASE3","title":"Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-02","conditions":"Breast Cancer","enrollment":6600},{"nctId":"NCT00087178","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-05","conditions":"Breast Cancer","enrollment":2722},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT02400567","phase":"PHASE2","title":"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":"Neoadjuvant Operable Breast Cancer","enrollment":125},{"nctId":"NCT02742051","phase":"PHASE2","title":"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-06","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT01593020","phase":"PHASE2","title":"Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-08-03","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT00553358","phase":"PHASE3","title":"Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01-05","conditions":"Neoplasms, Breast","enrollment":455},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT01656798","phase":"PHASE1","title":"Food Effect Study For New Formulation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2012-08","conditions":"Healthy","enrollment":12},{"nctId":"NCT03144947","phase":"PHASE2","title":"Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2016-11-29","conditions":"Cancer, Breast","enrollment":65},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":"Breast Cancer","enrollment":3509},{"nctId":"NCT00943462","phase":"","title":"Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM","status":"WITHDRAWN","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2009-06","conditions":"Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme","enrollment":""},{"nctId":"NCT01216111","phase":"PHASE3","title":"Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Triple Negative Breast Cancer","enrollment":647},{"nctId":"NCT04031703","phase":"PHASE3","title":"Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":"Breast Cancer","enrollment":647},{"nctId":"NCT01855828","phase":"PHASE2","title":"Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":"Her2-Positive Breast Cancer","enrollment":50},{"nctId":"NCT01836484","phase":"","title":"Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2012-06","conditions":"Surgically Staged Endometrial and Cervical Carcinoma, Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher, Endometrial Cancer","enrollment":162},{"nctId":"NCT00820547","phase":"PHASE2","title":"Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-01","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT03058939","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2018-11","conditions":"Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":""},{"nctId":"NCT01867229","phase":"","title":"Breast Cancer and Chemo-amennorhea","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2011-10","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT03888677","phase":"PHASE3","title":"Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer","status":"COMPLETED","sponsor":"Henrik Lindman","startDate":"2001-02","conditions":"Breast Cancer","enrollment":1535},{"nctId":"NCT00513292","phase":"PHASE3","title":"Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07","conditions":"HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer","enrollment":280},{"nctId":"NCT03688958","phase":"PHASE2","title":"Iodine Supplementation on Breast Cancer","status":"UNKNOWN","sponsor":"Universidad Nacional Autonoma de Mexico","startDate":"2005-03-15","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00772824","phase":"PHASE4","title":"Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2007-12","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00559845","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Breast Cancer","enrollment":56},{"nctId":"NCT03349177","phase":"PHASE2, PHASE3","title":"Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2017-11-27","conditions":"Breast Cancer, Pathological Complete Response, Neoadjuvant Chemotherapy","enrollment":200},{"nctId":"NCT02001506","phase":"PHASE3","title":"Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2012-11","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT01222052","phase":"PHASE3","title":"6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Martin-Luther-Universität Halle-Wittenberg","startDate":"2002-01","conditions":"Breast Cancer","enrollment":4150},{"nctId":"NCT01642771","phase":"PHASE3","title":"Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"China Breast Cancer Clinical Study Group","startDate":"2012-06","conditions":"Breast Cancer","enrollment":636},{"nctId":"NCT01824368","phase":"PHASE1, PHASE2","title":"Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.","status":"COMPLETED","sponsor":"Red de Terapia Celular","startDate":"2013-04","conditions":"Liver Transplantation, Immunosuppression","enrollment":10},{"nctId":"NCT02365805","phase":"PHASE2","title":"Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-04","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225},{"nctId":"NCT00524303","phase":"PHASE2","title":"Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Neoplasms, Breast","enrollment":100},{"nctId":"NCT00499603","phase":"PHASE2","title":"Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07","conditions":"Breast Cancer","enrollment":62},{"nctId":"NCT02846428","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT00450892","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-02","conditions":"Breast Cancer","enrollment":129},{"nctId":"NCT00131612","phase":"","title":"An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2002-01","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT01985841","phase":"PHASE2","title":"Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2011-10","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT02450058","phase":"PHASE3","title":"Adjuvant FEC Versus EP in Breast Cancer (MIG5)","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"1996-11","conditions":"Breast Cancer, Chemotherapy, Adjuvant","enrollment":1055},{"nctId":"NCT01563211","phase":"","title":"Predictive Model of Therapy Outcomes in Breast Cancer Patients","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-02","conditions":"Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.","enrollment":70},{"nctId":"NCT00593697","phase":"PHASE3","title":"The Synergism Or Long Duration (SOLD) Study","status":"COMPLETED","sponsor":"Finnish Breast Cancer Group","startDate":"2008-01","conditions":"Breast Neoplasms","enrollment":2168},{"nctId":"NCT00615602","phase":"PHASE3","title":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-10","conditions":"Breast Cancer","enrollment":489},{"nctId":"NCT00751868","phase":"PHASE2","title":"FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2008-09","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT00053911","phase":"PHASE3","title":"Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2002-11","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00256360","phase":"PHASE2","title":"Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2005-09","conditions":"Breast Cancer","enrollment":117},{"nctId":"NCT01740271","phase":"PHASE2","title":"A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients","status":"UNKNOWN","sponsor":"AHS Cancer Control Alberta","startDate":"2012-12","conditions":"Breast Neoplasms","enrollment":48},{"nctId":"NCT00425516","phase":"PHASE2","title":"Breast Cancer Treated by Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2007-01","conditions":"Individualized Chemotherapy","enrollment":264},{"nctId":"NCT02225652","phase":"PHASE2","title":"A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2010-09","conditions":"Women With Primary Breast Cancer","enrollment":11},{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754},{"nctId":"NCT01985724","phase":"PHASE3","title":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2007-10","conditions":"Breast Cancer","enrollment":650},{"nctId":"NCT02115152","phase":"PHASE2","title":"Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2014-06","conditions":"Stage II Breast Cancer, Stage III Breast Cancer","enrollment":100},{"nctId":"NCT00933517","phase":"PHASE2","title":"Assessment of the Efficacy of the Neoadjuvant Combination: \"Chemotherapy-Targeted Therapy\" in Breast Cancer.","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2009-09","conditions":"Pathological Response Rate","enrollment":62},{"nctId":"NCT00017095","phase":"PHASE3","title":"Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2001-03","conditions":"Breast Cancer","enrollment":1856},{"nctId":"NCT00054587","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2001-06","conditions":"Breast Cancer","enrollment":3010},{"nctId":"NCT00055679","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage I Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2002-08","conditions":"Breast Cancer","enrollment":1512},{"nctId":"NCT01537536","phase":"PHASE2","title":"Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2011-11","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT00047099","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2001-08","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT01159236","phase":"NA","title":"Molecular Triaging of Newly Diagnosed Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00038402","phase":"PHASE3","title":"Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-04","conditions":"Breast Cancer","enrollment":74},{"nctId":"NCT00520546","phase":"PHASE3","title":"Clinical Value of FEC-PET Combined With Endorectal MRI for Pre-therapeutic Staging of Prostate Cancer","status":"COMPLETED","sponsor":"Dr. Markus Hartenbach","startDate":"2007-12","conditions":"Prostate Cancer","enrollment":44},{"nctId":"NCT00670878","phase":"PHASE3","title":"Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-06","conditions":"Breast Cancer","enrollment":799},{"nctId":"NCT01180335","phase":"PHASE3","title":"Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-01","conditions":"Breast Cancer","enrollment":303},{"nctId":"NCT00336791","phase":"PHASE3","title":"Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":"Breast Cancer","enrollment":273},{"nctId":"NCT00544505","phase":"NA","title":"Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2007-09","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT00050167","phase":"PHASE1","title":"Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Breast Cancer","enrollment":603},{"nctId":"NCT00110695","phase":"PHASE2","title":"Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2005-04","conditions":"Breast Neoplasms","enrollment":66},{"nctId":"NCT00033683","phase":"PHASE2","title":"Combination Chemotherapy in Treating Women With Resected Breast Cancer","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2001-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00431080","phase":"PHASE3","title":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-08","conditions":"Breast Cancer","enrollment":478},{"nctId":"NCT00189644","phase":"PHASE3","title":"6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer","status":"UNKNOWN","sponsor":"Association Européenne de Recherche en Oncologie","startDate":"","conditions":"Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3638,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FEC","genericName":"FEC","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Breast cancer (adjuvant and neoadjuvant treatment), Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}